Investor Presentaiton

Operating Results for H1FY24 FY23 (Audited) H1 FY24 (unaudited) Australian dollars ('000'S) Group Revenue Glaucoma AlphaRET Corporate Group Glaucoma AlphaRET Corporate Group 16,661 364 17,025 10,062 77 10,139 GM 11,392 323 11,715 6,900 40 6,940 68% 69% Operating (17,676) (1,364) (2,225) (21,265) (9,433) (473) (1,213) (11,119) expenditure EBITDA (loss) (6,284) (1,041) (2,225) (9,550) (2,533) (433) (1,213) (4,179) FY23 (Audited) H1 FY24 (unaudited) Glaucoma only USA dollars ('000's) • shows leverage Commentary on H1FY24 compared with FY23 Improved gross margin Improved ratio of operating expenditure to revenue Revenue GM 11,273 6,619 7,548 4,539 67% 69% Operating (11,548) (6,128) expenditure EBITDA (4,000) (1,589) ne nova-eye.com | 25

View entire presentation